T1CH34 Stock Overview
Develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bio-Techne Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.44 |
| 52 Week High | US$15.42 |
| 52 Week Low | US$5.01 |
| Beta | 1.28 |
| 11 Month Change | 1.20% |
| 3 Month Change | n/a |
| 1 Year Change | 37.28% |
| 33 Year Change | -41.21% |
| 5 Year Change | n/a |
| Change since IPO | 7.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| T1CH34 | BR Life Sciences | BR Market | |
|---|---|---|---|
| 7D | -7.3% | 0% | 0% |
| 1Y | 37.3% | 0% | 0% |
Return vs Industry: T1CH34 exceeded the BR Life Sciences industry which returned -0.9% over the past year.
Return vs Market: T1CH34 exceeded the BR Market which returned -1.7% over the past year.
Price Volatility
| T1CH34 volatility | |
|---|---|
| T1CH34 Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in BR Market | 0% |
| 10% least volatile stocks in BR Market | 0% |
Stable Share Price: T1CH34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine T1CH34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 3,100 | Kim Kelderman | www.bio-techne.com |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
Bio-Techne Corporation Fundamentals Summary
| T1CH34 fundamental statistics | |
|---|---|
| Market cap | R$63.47b |
| Earnings (TTM) | R$875.92m |
| Revenue (TTM) | R$6.81b |
74.9x
P/E Ratio9.6x
P/S RatioIs T1CH34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| T1CH34 income statement (TTM) | |
|---|---|
| Revenue | US$1.17b |
| Cost of Revenue | US$397.65m |
| Gross Profit | US$773.94m |
| Other Expenses | US$623.26m |
| Earnings | US$150.68m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.95 |
| Gross Margin | 66.06% |
| Net Profit Margin | 12.86% |
| Debt/Equity Ratio | 14.0% |
How did T1CH34 perform over the long term?
See historical performance and comparisonDividends
0.5%
Current Dividend Yield34%
Payout RatioDoes T1CH34 pay a reliable dividends?
See T1CH34 dividend history and benchmarks| Bio-Techne dividend dates | |
|---|---|
| Ex Dividend Date | Nov 08 2024 |
| Dividend Pay Date | Nov 28 2024 |
| Days until Ex dividend | 15 days |
| Days until Dividend pay date | 5 days |
Does T1CH34 pay a reliable dividends?
See T1CH34 dividend history and benchmarks